Silverback Therapeutics (NASDAQ: SBTX)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-11 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.700 | ||||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Silverback Therapeutics (NASDAQ: SBTX) through any online brokerage.
There are no as such competitors for Silverback Therapeutics.
The latest price target for Silverback Therapeutics (NASDAQ: SBTX) was reported by Goldman Sachs on Monday, April 4, 2022. The analyst firm set a price target for 3.50 expecting SBTX to fall to within 12 months (a possible -18.41% downside). 7 analyst firms have reported ratings in the last year.
The stock price for Silverback Therapeutics (NASDAQ: SBTX) is $4.29 last updated June 28, 2022, 8:00 PM UTC.
There are no upcoming dividends for Silverback Therapeutics.
Silverback Therapeutics’s Q2 earnings are confirmed for Thursday, August 11, 2022.
There is no upcoming split for Silverback Therapeutics.
Silverback Therapeutics is in the Healthcare sector and Biotechnology industry. They are listed on the NASDAQ.